Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism

Area of Science:

• Metabolic regulation
• Hepatology
• Diabetes research

Background:

• Insulin resistance reduces the liver's ability to regulate glucose production.
• The precise role of Forkhead box protein 1 (FoxO1) in this process is unclear.
• Understanding FoxO1's function is crucial for metabolic disease research.

Purpose of the Study:

• To investigate the role of hepatic Forkhead box protein 1 (FoxO1) in insulin's regulation of liver metabolism.
• To explore the impact of FoxO1 deregulation on hepatic steatosis and glucose homeostasis in insulin resistance and diabetes.

Main Methods:

• Adenovirus-mediated and transgenic expression to manipulate FoxO1 activity in mice.
• Studied effects on hepatic gluconeogenesis, glycogen content, and fat deposition.
• Utilized db/db mice and high-fat-induced obesity models to assess insulin sensitivity and glucose tolerance.

Main Results:

• Increased FoxO1 activity augmented gluconeogenesis, decreased glycogen, and increased liver fat.
• FoxO1 gain of function impaired glucose tolerance.
• FoxO1 loss of function improved insulin sensitivity and glucose disposal in diabetic mice.
• FoxO1 deregulation (increased nuclear localization) observed in obese and diabetic mouse livers.
• FoxO1 up-regulated genes involved in fatty acid synthesis, contributing to hepatic fat infiltration.

Conclusions:

• Hepatic FoxO1 deregulation impairs insulin's metabolic control.
• This deregulation contributes to hepatic steatosis and metabolic dysfunction in diabetes.
• Targeting FoxO1 may offer therapeutic potential for metabolic diseases.